Search Results - "Lakhotia, Sanjay"

Recombinant Antidote for Reversal of Anticoagulation by Factor Xa Inhibitors by Lu, Genmin, DeGuzman, Francis R., Lakhotia, Sanjay, Hollenbach, Stanley J, Phillips, David R, Sinha, Uma

“…Individuals anticoagulated with warfarin or heparin are typically treated with specific antidotes such as vitamin K or protamine, respectively, if they bleed…”
Get full text

A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer by Aggarwal, Rahul R, Schweizer, Michael T, Nanus, David M, Pantuck, Allan J, Heath, Elisabeth I, Campeau, Eric, Attwell, Sarah, Norek, Karen, Snyder, Margo, Bauman, Lisa, Lakhotia, Sanjay, Feng, Felix Y, Small, Eric J, Abida, Wassim, Alumkal, Joshi J

“…ZEN-3694 is a bromodomain extraterminal inhibitor (BETi) with activity in androgen-signaling inhibitor (ASI)-resistant models. The safety and efficacy of…”
Get full text

BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program by Kim, Dae-Hwan, Sun, Duanchen, Storck, William K, Welker Leng, Katherine, Jenkins, Chelsea, Coleman, Daniel J, Sampson, David, Guan, Xiangnan, Kumaraswamy, Anbarasu, Rodansky, Eva S, Urrutia, Joshua A, Schwartzman, Jacob A, Zhang, Chao, Beltran, Himisha, Labrecque, Mark P, Morrissey, Colm, Lucas, Jared M, Coleman, Ilsa M, Nelson, Peter S, Corey, Eva, Handelman, Samuel K, Sexton, Jonathan Z, Aggarwal, Rahul, Abida, Wassim, Feng, Felix Y, Small, Eric J, Spratt, Daniel E, Bankhead, 3rd, Armand, Rao, Arvind, Gesner, Emily M, Attwell, Sarah, Lakhotia, Sanjay, Campeau, Eric, Yates, Joel A, Xia, Zheng, Alumkal, Joshi J

“…Lineage plasticity in prostate cancer-most commonly exemplified by loss of androgen receptor (AR) signaling and a switch from a luminal to alternate…”
Get full text

A randomized mCRPC phase 2b study of the BET bromodomain inhibitor (BETi) zen-3694 and enzalutamide vesus enzalutamide by Aggarwal, Rahul Raj, Schweizer, Michael Thomas, Nanus, David M., Attwell, Sarah, Campeau, Eric, Johnson, Emily, Wegge, Philip, Bauman, Lisa, Silverman, Michael H., Xu, Vandy, Zhu, Helena, Snyder, Margo, Lakhotia, Sanjay, Alumkal, Joshi J.

“…Abstract only TPS201 Background: Androgen receptor signaling inhibitors (ARSI), such as enzalutamide (Enza), and abiraterone (Abi), are standard therapies for…”
Get full text

Modulating BET Bromodomain Inhibitor ZEN‐3694 and Enzalutamide Combination Dosing in a Metastatic Prostate Cancer Patient Using CURATE.AI, an Artificial Intelligence Platform by Pantuck, Allan J., Lee, Dong‐Keun, Kee, Theodore, Wang, Peter, Lakhotia, Sanjay, Silverman, Michael H., Mathis, Colleen, Drakaki, Alexandra, Belldegrun, Arie S., Ho, Chih‐Ming, Ho, Dean

“…Combination chemotherapy is a cornerstone of cancer treatment. Optimizing its effectiveness requires dose‐ and time‐dependent regulation of drug synergy. In…”
Get full text

A phase 1b/2 study of the BET inhibitor ZEN-3694 in combination with talazoparib for treatment of patients with TNBC without gBRCA1/2 mutations by Aftimos, Philippe Georges, Oliveira, Mafalda, Punie, Kevin, Boni, Valentina, Hamilton, Erika P., Gucalp, Ayca, Shah, Payal D, de Miguel, Maria J., Sharma, Priyanka, Bauman, Lisa, Campeau, Eric, Attwell, Sarah, Snyder, Margo, Norek, Karen, Johnson, Emily, Silverman, Michael H., Lakhotia, Sanjay, Domchek, Susan M., Litton, Jennifer Keating, Robson, Mark E.

“…1023 Background: Metastatic triple negative breast cancer (mTNBC) is an aggressive and heterogeneous cancer with limited therapeutic options. PARP inhibitors…”
Get full text

Abstract 1282: Overcoming resistance to inhibitors of CDK4/6 and BET in estrogen receptor-positive breast cancer by Cosín, Marc, Tian, Tian, Oliveros, Winona, Kharenko, Olesya A., van der Horst, Edward H., Patel, Reena G., Calosing, Cyrus, Campeau, Eric, Jahagirdar, Ravi, Lakhotia, Sanjay, Melé, Marta, Palafox, Marta, Arribas, Joaquín, Oliveira, Mafalda, Saura, Cristina, Serra, Violeta, Peiro, Sandra

“…Three inhibitors of CDK4/6 kinases have been recently approved for use in combination with endocrine therapy. These inhibitors considerably increase the…”
Get full text

A Phase 1b/2a Study of the Pan-BET Bromodomain Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer by Aggarwal, Rahul, Schweizer, Michael T., Nanus, David M., Pantuck, Allan, Heath, Elisabeth, Campeau, Eric, Attwell, Sarah, Norek, Karen, Snyder, Margo, Bauman, Lisa, Lakhotia, Sanjay, Feng, Felix Y., Small, Eric J., Abida, Wassim, Alumkal, Joshi

Get full text

Abstract PS11-10: A Phase 1b/2 Study of the BET inhibitor ZEN003694 in combination with talazoparib for treatment of patients with TNBC without gBRCA1/2 mutations by Aftimos, Philippe, Oliveira, Mafalda, Punie, Kevin, Boni, Valentina, Hamilton, Erika, Gucalp, Ayca, Shah, Payal, Mina, Lida, Sharma, Priyanka, Bauman, Lisa, Campeau, Eric, Attwell, Sarah, Snyder, Margo, Norek, Karen, Czibere, Akos, Yu, Yanke, Silverman, Michael H, Lakhotia, Sanjay, Domchek, Susan, Litton, Jennifer, Robson, Mark

“…Background: Metastatic triple-negative breast cancer (TNBC) is an aggressive and heterogeneous cancer with limited therapeutic options. PARP inhibitors (PARPi)…”
Get full text

Abstract CT095: A Phase Ib/IIa study of the BET bromodomain inhibitor ZEN-3694 in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) by Aggarwal, Rahul, Abida, Wassim, Schweizer, Michael, Pantuck, Allan, Nanus, David, Heath, Elisabeth, Lakhotia, Sanjay, Hansen, Henrik, Silverman, Michael, Bauman, Lisa, Snyder, Margo, Campeau, Eric, Norek, Karen, Attwell, Sarah, O'Farrell, Marie, Smith, Steve, Wegge, Philip, Jahagirdar, Ravi, Alumkal, Joshi

“…Background: Abiraterone (ABI) and enzalutamide (ENZ) have significant activity in mCRPC yet demonstrate frequent cross-resistance limiting efficacy of…”
Get full text

Abstract LB-038: Preclinical development and clinical validation of a whole blood pharmacodynamic marker assay for the BET bromodomain inhibitor ZEN-3694 in metastatic castration-resistant prostate cancer (mCRPC) patients by Tsujikawa, Laura, Norek, Karen, Calosing, Cyrus, Attwell, Sarah, Gilham, Dean, Sharma, Nimisha, Tobin, Jennifer, Haager, Michelle, Jahagirdar, Ravi, Lakhotia, Sanjay, Hansen, Henrik C., Campeau, Eric

“…Detection of drug activity in patients is essential to confirm its mechanism of action, as well as to ensure proper target engagement at the selected dose to…”
Get full text

Abstract C86: The clinical candidate ZEN-3694, a novel BET bromodomain inhibitor, is efficacious in the treatment of a variety of solid tumor and hematological malignancies, alone or in combination with several standard of care and targeted therapies by Attwell, Sarah, Campeau, Eric, Jahagirdar, Ravi, Kharenko, Olesya, Norek, Karen, Tsujikawa, Laura, Calosing, Cyrus, Patel, Reena, Gesner, Emily, Lakhotia, Sanjay, Hansen, Henrik

“…ZEN-3694 is an orally bioavailable small molecule discovered and developed from a BET bromodomain inhibitor discovery platform. In vitro, ZEN-3694 selectively…”
Get full text

Abstract LB-207: Preclinical characterization of ZEN-3694, a novel BET bromodomain inhibitor entering phase I studies for metastatic castration-resistant prostate cancer (mCRPC) by Attwell, Sarah, Jahagirdar, Ravi, Norek, Karen, Calosing, Cyrus, Tsujikawa, Laura, Kharenko, Olesya A., Patel, Reena G., Gesner, Emily M., Corey, Eva, Nguyen, Holly M., Lakhotia, Sanjay, Hansen, Henrik C., Campeau, Eric

“…Metastatic castration resistant prostate cancer (mCRPC) is a major unmet medical need due to its widespread occurrence and incurable status. Current standard…”
Get full text

Artificial Intelligence: Modulating BET Bromodomain Inhibitor ZEN‐3694 and Enzalutamide Combination Dosing in a Metastatic Prostate Cancer Patient Using CURATE.AI, an Artificial Intelligence Platform (Adv. Therap. 6/2018) by Pantuck, Allan J., Lee, Dong‐Keun, Kee, Theodore, Wang, Peter, Lakhotia, Sanjay, Silverman, Michael H., Mathis, Colleen, Drakaki, Alexandra, Belldegrun, Arie S., Ho, Chih‐Ming, Ho, Dean

“…The use of artificial intelligence and digital health has opened the doors to developing optimal treatment strategies for a broad spectrum of diseases. In…”
Get full text

A flow cytometric evaluation of hydrodynamic damage in animal cell bioreactors by Lakhotia, Sanjay

“…Flow cytometry was used to examine physiological responses of cells to hydrodynamic forces in surface aerated stirred tank bioreactors. Chinese hamster ovary…”
Get full text